Research Topics
Species | Adam D CohenSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Anti-GITR antibodies--potential clinical applications for tumor immunotherapyDavid A Schaer
Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue, New York, NY 10065, USA
Curr Opin Investig Drugs 11:1378-86. 2010..This review discusses the role of GITR as a potential target for immunomodulatory therapy, as well as the research involved in understanding the mechanisms of anti-GITR therapy and current progress in translation into the clinic...
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trialAdam D Cohen
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 139:224-33. 2007..Risk-adapted SCT with adjuvant thal/dex is feasible and results in low TRM and high haematological and organ response rates in AL patients...
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunityAdam D Cohen
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Res 66:4904-12. 2006..Finally, this effect on vaccine-induced CD8(+) T-cell responses was partially independent of CD4(+) T cells (both helper and regulatory), consistent with a direct costimulatory effect on the effector CD8(+) cells themselves...
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulationAdam D Cohen
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 5:e10436. 2010..These findings provide further support for the continued development of agonist anti-GITR mAbs as an immunotherapeutic strategy for cancer...
DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantationMiguel Angel Perales
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Immunol 177:4159-67. 2006..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD...
Immune rejection of mouse tumors expressing mutated selfFei Duan
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer Res 69:3545-53. 2009..Immune modulation, such as inducing GITR signaling, is required to enhance CD8(+) T-cell responses to specific mutations and to lead to tumor rejection...
Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscopeDavid A Schaer
Swim Across America Laboratory, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, New York, United States of America
PLoS ONE 6:e21214. 2011..Together, these data indicate that lack of anti-tumor efficacy is not solely due to ignorance of self antigen in the tumor microenvironment but rather to active immunosuppressive influences preventing a protective immune response...
Optimization of a self antigen for presentation of multiple epitopes in cancer immunityJose A Guevara-Patino
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Clin Invest 116:1382-90. 2006....
DNA vaccines against cancerRodica Stan
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Hematol Oncol Clin North Am 20:613-36. 2006..It gives a brief history and then discusses the proposed mechanism of action, preclinical and clinical studies, and methods of enhancing the immune responses induced by DNA vaccines...
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosisDaniel Hirschhorn-Cymerman
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Exp Med 206:1103-16. 2009..Closer examination revealed that diminished intratumoral T reg cell levels resulted from hyperactivation and T reg cell-specific apoptosis. Thus, we propose that CTX and OX40 engagement represents a novel and rational chemoimmunotherapy...
DNA vaccines for melanomaAdam D Cohen
Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
Cancer Chemother Biol Response Modif 22:761-8. 2005
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosisRaymond L Comenzo
N Engl J Med 358:92; author reply 92-3. 2008
Research Grants
- Targeting GITR for Tumor ImmunotherapyAdam Cohen; Fiscal Year: 2007..Gaining greater mechanistic understanding of the effects of anti-GITR antibody on tumor immunity will allow for more rational translation of this promising immunotherapeutic approach to the clinic. ..
